Tandem Diabetes Care (TNDM) Current Deferred Revenue (2013 - 2026)

Tandem Diabetes Care's Current Deferred Revenue history runs 14 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 18.43% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 18.43% YoY) and the FY2025 annual result came in at $9.5 million, down 19.47% from the prior year.
• Current Deferred Revenue was $9.0 million for Q1 2026 at Tandem Diabetes Care, down from $9.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $44.0 million in Q4 2023 and bottomed at $1.1 million in Q1 2024.
• A 5-year average of $16.5 million and a median of $11.7 million in 2022 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue plunged 95.3% — and 2025, when it surged 897.91%.
• Tandem Diabetes Care's Current Deferred Revenue stood at $18.8 million in 2022, then soared by 133.55% to $44.0 million in 2023, then slumped by 73.11% to $11.8 million in 2024, then slipped by 19.47% to $9.5 million in 2025, then declined by 6.01% to $9.0 million in 2026.
• Business Quant data shows TNDM's Current Deferred Revenue at $9.0 million in Q1 2026, $9.5 million in Q4 2025, and $9.8 million in Q3 2025.